NCT06594367Completed
A Possible Founding PKD2 Mutation Associated With Variable Phenotypes of ADPKD in Bergamo Province
Source: ClinicalTrials.gov · Last updated 23 Mar 2026
Brief summary (registry, in English)
This is an observational study aimed at assessing if a new and specific heterozygous deletion detected at PKD2 gene is associated to a "founder effect" in 10 Autosomal dominant polycystic kidney disease (ADPKD) patients, and at investigating the genotype-phenotype correlation in the families sharing the same PKD2 breakpoint site.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 10 (actual)
- First submitted
- 2 Sept 2024
- Start date
- 22 Jan 2025
- Primary completion date
- 17 Oct 2025
- Lead sponsor
- Mario Negri Institute for Pharmacological Research
- Diseases
- Polycystic kidney disease
- NCT number
- NCT06594367
What you commit to
- Study type: Observational
- Participants enrolled: 10
- From 22 Jan 2025 to the primary completion date, 17 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Healthy patients
Who the study is looking for
- Patients with ADPKD
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical Research Centre for Rare Diseases Aldo e Cele Daccò Coordinator of this site? Confirm its status | Ranica | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.